**Differential Effects of Propofol and Sevoflurane on Ischemia-induced Ventricular Arrhythmias and Phosphorylated Connexin 43 Protein in Rats**

Naoyuki Hirata, M.D.,* Noriaki Kanaya, M.D., M.B.A., Ph.D.,† Noriko Kamada, M.D., Ph.D.,‡ Saori Kimura, M.D., Ph.D.,‡ Akiyoshi Namiki, M.D., Ph.D.§

**Background:** The effects of anesthetics on ischemia-induced ventricular arrhythmias remain poorly studied. This study investigated the effects of propofol and sevoflurane on the survival rate and morbidity as a result of ventricular arrhythmias, and defined a possible mechanism for the arrhythmogenic properties of anesthetics during acute myocardial ischemia.

**Methods:** Under anesthesia with intraperitoneal sodium pentobarbital, Sprague-Dawley rats underwent 30 min of left anterior descending coronary artery ligation. The rats were divided into a low-dose propofol (Prop-LD) group (39 mg·kg⁻¹·hr⁻¹, n = 18), a high-dose propofol group (78 mg·kg⁻¹·hr⁻¹, n = 18), a sevoflurane group (2.5%, n = 18) and a control group (n = 18). The survival rate and morbidity as a result of ventricular arrhythmias were determined, and the amount of phosphorylated connexin 43 protein was measured 30 min after coronary artery ligation.

**Results:** The survival rate was 83% (15 of 18), 94% (17 of 18), 89% (16 of 18), and 67% (12 of 18, P = 0.038 vs. Prop-LD) in the control, Prop-LD, high-dose propofol, and sevoflurane groups, respectively. Sustained ventricular tachycardia was observed in 83% (15 of 18), 39% (7 of 18, P = 0.011 vs. control), 50% (9 of 18, P = 0.039 vs. control) and 94% (17 of 18, P < 0.01 vs. Prop-LD) in the control, Prop-LD, high-dose propofol, and sevoflurane groups, respectively. Immunoblotting showed a marked reduction in the amount of phosphorylated connexin 43 in the control and sevoflurane groups, as compared with the Prop-LD and high-dose propofol groups (P < 0.05).

**Conclusion:** The authors’ results suggest that propofol preserves connexin 43 phosphorylation during acute myocardial ischemia, as compared with sevoflurane, and this might protect the heart from serious ventricular arrhythmias during acute coronary occlusion.

Propofol and sevoflurane are widely used during anesthesia in patients with ischemic heart disease. These patients are at high risk for perioperative myocardial ischemia (MI), which is a major factor leading to lethal ventricular arrhythmias. Anesthetic agents such as halothane, enfurane, and isofluorane are known to facilitate reentrant excitation in subjects with MI. However, the effects of propofol and sevoflurane on ventricular arrhythmias related to MI remain unknown, even though many studies have suggested that these anesthetics have cardioprotective effects on functional, metabolic, and histologic changes caused by ischemia or reperfusion injury.

In the ischemic myocardium there is a reduction of tissue pH, an increase in interstitial potassium levels and intracellular calcium concentration, and neurohumoral changes that all contribute to the development of electrical instability and lethal cardiac arrhythmias. In particular, cell-to-cell electrical uncoupling of ventricular myocytes plays an important role in arrhythmogenesis during acute MI.

Connexin 43 (Cx 43), a principal cardiac gap-junction channel protein, has been implicated in the electrical coupling of cardiac muscle cells. Many studies have demonstrated that ischemia and heart failure reduce Cx43 expression, and Cx43 undergoes progressive dephosphorylation with a time course similar to that of electrical uncoupling during acute MI. Moreover, transplantation of Cx43-expressing embryonic cardiomyocytes in myocardial infaracts protects against the induction of ventricular tachycardia in mice. These results indicate that Cx43 dysfunction in cardiomyocytes could be an important factor that contributes to the substrate for lethal ventricular arrhythmias.

In this study, we examined the effects of propofol and sevoflurane on ventricular tachyarrhythmias during MI in vivo. Furthermore, we clarified whether these anesthetics affect Cx43 dephosphorylation during MI.

**Materials and Methods**

The experimental protocols used in this study were approved by the Sapporo Medical University Animal Care and Use Committee (Sapporo, Hokkaido, Japan).

**Surgical Preparation and Coronary Artery Ligation**

Male Sprague-Dawley rats (250-300 g, aged 7–9 weeks) were assigned to the following 6 treatment groups: a sham-operated group (Sham, n = 5), a control group (n = 18), a low-dose propofol (Prop-LD) group (n = 18), a high-dose propofol (Prop-HD) group (n = 18) and a sevoflurane (Sevo) group (n = 18). Moreover, to estimate the effects of propofol on parasympathetic activity, rats with MI were treated with IV atropine before the administration of a low dose of propofol (Prop-Atr, n = 18).

After induction of anesthesia with 50 mg/kg intraperitoneal sodium pentobarbital, the rats were intubated and
ventilated artificially with a volume-controlled rodent respirator (Model 683; Harvard Apparatus, Holliston, MA) at 65-80 strokes/min to maintain normal arterial levels of PO2, partial pressure of carbon dioxide (PCO2) and pH. A polyethylene catheter was inserted into the femoral artery for direct measurement of blood pressure, and the femoral vein was cannulated for drug administration. A thoracotomy was performed horizontally in the fourth intercostal space, and a suture was loosely tied around the left anterior descending (LAD) coronary artery. Electrodes were placed to allow the measurement of a Lead II electrocardiogram. Mean blood pressure (MBP) and heart rate (HR) were recorded every 5 min throughout the experiment. Body temperature was continuously monitored with a rectal thermometer and maintained at 37°C using a heating pad and overhead lamp.

After preparation for LAD ligation, drugs were administered according to the group assignment. In the Prop-LD group, propofol was continuously infused IV at a sedative dose (39 mg · kg⁻¹ · hr⁻¹), which was determined by using the tail-clamp technique. In the Sevo group, rats were exposed to 2.5% sevoflurane that corresponds to a minimum alveolar anesthetic concentration of 1, which was also determined using the tail-clamp technique. In the Sham, Control, and Sevo groups, Intralipid (Pharmacia AB, Stockholm, Sweden) was continuously infused IV (390 mg · kg⁻¹ · hr⁻¹) so that the volume of injectate would be the same as in the Prop-LD group. After preparation for LAD ligation, drugs were administered according to the group assignment. In the Prop-LD group, propofol was continuously infused IV at a sedative dose (39 mg · kg⁻¹ · hr⁻¹), which was determined by using the tail-clamp technique. In the Sevo group, rats were exposed to 2.5% sevoflurane that corresponds to a minimum alveolar anesthetic concentration of 1, which was also determined using the tail-clamp technique. In the Sham, Control, and Sevo groups, Intralipid (Pharmacia AB, Stockholm, Sweden) was continuously infused IV (390 mg · kg⁻¹ · hr⁻¹) so that the volume of injectate would be the same as in the Prop-LD group.

Determination of Ischemic Areas
At the end of 30 min of LAD ligation or at the time of death as a result of VF, the heart was removed and perfused retrogradely with 10 ml of 0.9% saline to wash out blood from the coronary circulation. Then, 2 ml of 2% Evans blue was injected to confirm the lack of perfusion of the ischemic area. The hearts were excised and frozen and then sliced into 2-mm-thick transverse sections from apex to base. The ischemic area was determined by negative staining with Evans blue. Since myocardial infarction is difficult to measure after only 30 min of coronary ligation, no attempt was made to separate ischemic from infarcted tissue. The ischemic area was measured using NIH image software (version 1.62; National Institutes of Health, Bethesda, MD).

Protein Preparation and Immunoblotting
Because the hearts injected within Evans blue could not be used for immunoblotting, we analyzed another 5 hearts in each group for Cx43 levels.

The ventricular tissues were suspended in 40 ml of ice-cold 10% trichloroacetic acid and homogenized with a tissue homogenizer (2 bursts, 30 s each). Homogenates were centrifuged at 10,000 g for 10 min at 4°C, and protein content was determined using detergent-compatible protein assay (Bio-Rad Laboratories Inc., Hercules, CA) with bovine serum albumin. The proteins were then put in a 3× sample buffer consisting of 0.2 M Tris-HCl (pH 6.8), 4% sodium dodecylsulfate, 8 M urea, 0.1 M dithiothreitol, and 0.01% bromophenol blue. Equal amounts of protein per lane were loaded onto a 15% polyacrylamide gel and separated by electrophoresis at 30 mA/gel for 60 min with a running buffer containing 25 mM Tris, 192 mM glycine, and 0.1% sodium dodecyl sulfate. Molecular weight markers (Amersham Biosciences, Buckinghamshire, United Kingdom) were used in each gel. Proteins were transferred to a polyvinylidene difluoride membrane (Immobilon-P; Millipore Corp., Bedford, MA) at 36 V for 4 h using a transfer buffer containing 0.01 M 3-[cyclohexylamino]-1-propanesulfonic acid (pH 11)-10% methanol. The blots were incubated with 5% nonfat dry milk in phosphate-buffered saline (PBS; pH 7.4) for 1 h at room temperature to block nonspecific binding of the antibodies. Then the membrane preparation was incubated with a rabbit polyclonal anti-Cx43 antibody (1:1,000 dilution; Zymed Lab-
oratories, South San Francisco, CA) in 0.1% bovine serum albumin and placed in PBS overnight at 4°C. The concentration of actin, a housekeeping protein, was also measured using rabbit antiactin antibody (1:1,000; Sigma Chemical Co., St. Louis, MO). The blot was washed for 30 min with 2 changes of 2% nonfat dry milk-0.1% Tween-20 in PBS and then incubated with a goat antirabbit immunoglobulin G secondary antibody conjugated to horseradish peroxidase (1:5,000; DAKO, Glostrup, Denmark) in 0.1% bovine serum albumin and placed in PBS overnight at 4°C. The concentration of Cx43 were compared using one-way analysis of variance, followed by a Tukey test. Differences in hemodynamic areas and tissue concentration of Cx43 were compared using one-way analysis of variance, followed by a Tukey test. Differences in hemodynamics were compared by 2-way analysis of variance with repeated measures and a Tukey test. A P value of less than 0.05 was considered statistically significant.

### Results

#### Hemodynamic Parameters and Ischemic Areas

Table 1 shows hemodynamics changes. In the Prop-HD and Sevo groups, MBP and HR were lower before and during LAD ligation, as compared with the Control group. There were no differences in hemodynamics among the Control, Prop-LD, and Prop-Atr groups.

Table 2 shows arterial levels of Po2, Pco2, and pH, and the ischemic area in each group. There were no significant differences in the blood gas analyses during LAD ligation. Ischemic areas were 56 ± 7%, 55 ± 8%, 53 ± 5%, 59 ± 7%, and 53 ± 7% in the Control, Prop-LD, Prop-HD, Prop-Atr, and Sevo groups, respectively. There were no significant differences in ischemic areas among all the groups (P = 0.88).

### Table 1. Hemodynamics before and after 30 min of LAD Ligation

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Before</th>
<th>After 30-min Ligation</th>
<th>Before</th>
<th>After 30-min Ligation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>5</td>
<td>119 ± 14</td>
<td>120 ± 12</td>
<td>398 ± 25</td>
<td>414 ± 27</td>
</tr>
<tr>
<td>Control</td>
<td>18</td>
<td>120 ± 15</td>
<td>110 ± 9</td>
<td>405 ± 24</td>
<td>398 ± 43</td>
</tr>
<tr>
<td>Propofol low dose</td>
<td>18</td>
<td>117 ± 13</td>
<td>96 ± 15</td>
<td>412 ± 22</td>
<td>387 ± 34</td>
</tr>
<tr>
<td>Propofol high dose</td>
<td>18</td>
<td>85 ± 14*</td>
<td>78 ± 24*</td>
<td>353 ± 25*</td>
<td>360 ± 48*</td>
</tr>
<tr>
<td>Propofol-atropine</td>
<td>18</td>
<td>110 ± 8</td>
<td>103 ± 10</td>
<td>405 ± 20</td>
<td>389 ± 22</td>
</tr>
<tr>
<td>Sevoflurane</td>
<td>18</td>
<td>82 ± 9*</td>
<td>80 ± 22*</td>
<td>325 ± 31*</td>
<td>324 ± 45*</td>
</tr>
</tbody>
</table>

The hemodynamic parameters recorded before ligation were obtained 15 minutes after drug/anesthetic administration. All values are mean ± SD.

#### Data Analysis

The time of death as a result of VF and onset of the first run of VT (arrhythmia score, more than 3) was analyzed by the Kaplan-Meier method, and the groups were compared with the Mantel-Haenzel log-rank test. Arrhythmia scores were presented as the median and interquartile range, and the groups were compared with a Kruskal-Wallis test. Proteins were quantified using a densitometer to give the Cx43/actin ratio. The Cx43/actin ratio was determined for both phosphorylated Cx43 (43kDa) and nonphosphorylated Cx43 (41kDa). Hemodynamics, ischemic areas, and Cx43/actin were presented as the mean ± SD. Differences in ischemic areas and tissue concentration of Cx43 were compared using one-way analysis of variance, followed by a Tukey test. Differences in hemodynamics were compared by 2-way analysis of variance with repeated measures and a Tukey test. A P value of less than 0.05 was considered statistically significant.

### Table 2. Blood Gas Analyses and Ischemic Area

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Before</th>
<th>After 30-min Ligation</th>
<th>Before</th>
<th>After 30-min Ligation</th>
<th>Ischemic Area, % LV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>5</td>
<td>7.43 ± 0.02</td>
<td>7.42 ± 0.05</td>
<td>103 ± 7</td>
<td>102 ± 9</td>
<td>39 ± 2</td>
</tr>
<tr>
<td>Control</td>
<td>18</td>
<td>7.44 ± 0.02</td>
<td>7.41 ± 0.12</td>
<td>104 ± 5</td>
<td>101 ± 8</td>
<td>38 ± 3</td>
</tr>
<tr>
<td>Propofol low dose</td>
<td>18</td>
<td>7.43 ± 0.03</td>
<td>7.42 ± 0.08</td>
<td>102 ± 6</td>
<td>102 ± 9</td>
<td>38 ± 2</td>
</tr>
<tr>
<td>Propofol high dose</td>
<td>18</td>
<td>7.42 ± 0.02</td>
<td>7.41 ± 0.15</td>
<td>103 ± 7</td>
<td>99 ± 8</td>
<td>39 ± 3</td>
</tr>
<tr>
<td>Propofol-atropine</td>
<td>18</td>
<td>7.44 ± 0.02</td>
<td>7.43 ± 0.10</td>
<td>104 ± 7</td>
<td>101 ± 7</td>
<td>38 ± 2</td>
</tr>
<tr>
<td>Sevoflurane</td>
<td>18</td>
<td>7.42 ± 0.05</td>
<td>7.41 ± 0.12</td>
<td>100 ± 5</td>
<td>98 ± 9</td>
<td>38 ± 4</td>
</tr>
</tbody>
</table>

All values are mean ± SD. There were no significant differences in pH, Po2, Pco2, and ischemic area among all the groups.

LV = left ventricle.
In Vivo Arrhythmia Study

Figure 1 shows the survival rates in all experiments. The survival rate during the 30-min LAD ligation was 83% (15 of 18), 94% (17 of 18), 89% (16 of 18), 83% (15 of 18), and 67% (12 of 18) in the Control, low-dose propofol (Prop-LD), high-dose propofol (Prop-HD), propofol with atropine (Prop-Atr), and sevoflurane (Sevo) groups, respectively. A low dose of propofol significantly decreased the mortality rate, as compared with sevoflurane (P < 0.05, Prop-LD vs. Sevo group). §P < 0.05 versus Prop-LD.

In our study, the Control group was an Intralipid group and not a true control group without any drugs. To evaluate the possibility of modification of ischemia-induced arrhythmias by Intralipid itself, we induced ischemia in a group with normal saline-infused IV (3.9 ml/hr, n = 7) instead of Intralipid in preliminary experiments. The survival rate during the 30-min LAD ligation was 71% (5 of 7), and sustained VT was observed in 86% (6 of 7) of the rats in the normal saline group. There were no significant differences in hemodynamics, arrhythmia scores (data not shown), survival rate, and incidence of sustained VT between the Intralipid control group and the normal saline group.

Prop-HD groups had significantly lower arrhythmia scores (P < 0.05 vs. the Prop-Atr or Sevo group).

In our study, the Control group was an Intralipid group and not a true control group without any drugs. To evaluate the possibility of modification of ischemia-induced arrhythmias by Intralipid itself, we induced ischemia in a group with normal saline-infused IV (3.9 ml/hr, n = 7) instead of Intralipid in preliminary experiments. The survival rate during the 30-min LAD ligation was 71% (5 of 7), and sustained VT was observed in 86% (6 of 7) of the rats in the normal saline group. There were no significant differences in hemodynamics, arrhythmia scores (data not shown), survival rate, and incidence of sustained VT between the Intralipid control group and the normal saline group.

Effects of Anesthetics on Cx43 Expression

To examine the possibility that the beneficial effect of propofol on ischemia-induced arrhythmias is caused by preventing the loss of phosphorylated Cx43, we measured the tissue concentration of phosphorylated Cx43 after 30 min of LAD ligation. The polyclonal anti-Cx43 antibody in the present study showed closely spaced bands migrating between 43 and 46 kDa, and a faint band migrating at 41 kDa. Previous reports demonstrated that higher and lower molecular weight bands represent phosphorylated (P-Cx43) and nonphosphorylated isoforms of Cx43 (NP-Cx43), respectively. Figure 4A shows a representative immunoblot prepared with
polyclonal anti-Cx43 and antiactin antibodies. P-Cx43 (43 kDa band) decreased and NP-Cx43 (41 kDa band) increased after 30 min of LAD ligation in all but the Sham group. The levels of P-Cx43 in the Prop-LD and Prop-HD groups were preserved, as compared with the Control, Prop-Atr, and Sevo groups. The levels of NP-Cx43 (41 kDa band) in the Control, Prop-Atr, and Sevo groups increased more than that of the Prop-LD and Prop-HD groups. Optical density analysis of the Cx43/actin ratio revealed that Prop-LD and Prop-HD prevented the loss of P-Cx43 and the increased expression of NP-Cx43, as compared with the Control, Prop-Atr, and Sevo groups. Figure 4B shows that the levels of P-Cx43 and NP-Cx43 were not significantly different among the Control and Prop-Atr and Sevo groups.

Discussion

The present study demonstrates that propofol attenuates acute ischemia-induced arrhythmias via modulation of a principal cardiac gap-junction protein, Cx43. Continuous infusion of propofol reduced morbidity as a result of acute ischemia-induced ventricular tachyarhythmias and inhibited loss of the phosphorylated isoform of Cx43. Moreover, these antiarrhythmic effects of propofol were blocked by atropine.

Anesthetics and Arrhythmogenic Properties

In humans, there have been case reports of the antiarrhythmic effects of propofol in patients with VT, atrial fibrillation, and supraventricular tachycardia. These antiarrhythmic effects of propofol are likely explained by increased cardiac parasympathetic tone and reduced cardiac sympathetic tone. Direct effects of propofol on the cardiac conduction system have been demonstrated in various animal studies in vitro. However, the effects of propofol on ischemia-induced arrhythmias have not been elucidated in previous studies.

Although the manifestation of the ischemia-induced arrhythmias is the result of a variety of interacting factors, sympathetic overactivity is important in the generation of acute and chronic ischemia-induced arrhythmias. MI causes a spatially uneven increase in sympathetic nerve activity in the heart, resulting in regional variation in the release and, consequently, variations in tissue levels
of sympathetic neurotransmitters (epinephrine and nor-
epinephrine). Nonuniform elevation of neurotransmit-
ters, through alterations in the expression of L-type Ca$$^{2+}$$ channels and K$$^+$$ channels, creates electrophysiologi-
ical heterogeneity between the ischemic and nor-
mal myocardium. Furthermore, locally elevated levels of neurotransmitters increase coronary arterial tone, thereby critically reducing coronary perfusion under conditions of increased oxygen demand (physical and/or emotional stress) and causing regional ischemia, which contributes to the development of ar-
rhythmias. Many studies have demonstrated that sympa-
thetic blockade by β-blockers left stellate ganglion blockade, and thoracic epidural anesthesia is beneficial in postmyocardial infarction patients. These results suggest an important role of the sympathetic nervous system in the pathogenesis of ischemia-induced arrhythmias.

In the present study, it is noteworthy that propofol’s action, including the action on Cx43, was blocked by atropine. It is possible that the antiarrhythmic effect of propofol in our results was because of a reduction in sympathetic tone leading to a dominance of parasympathetic tone. Propofol is also well known to inhibit action potential duration (APD). Sarcolemmal L-type Ca$$^{2+}$$ channels, K$$^+$$ channels, and the Ca$$^{2+}$$ uptake capacity of the sarcoplasmic reticulum; thus, propofol has multiple sites of action in the cardiac cells that could contribute to antiarrhythmic effects in our study. In the ischemic myocardium, it is commonly believed that an increase in membrane K$$^+$$ conductance via activation of adenosine triphosphate (ATP)-dependent potassium (K$$_{ATP}$$) channels causes APD shortening, which is deeply involved in repolarization and refractoriness to conduc-
tion. The dispersion of repolarization and refractori-
ness to conduction between the ischemic and normal zone has been implicated in the generation of ventricular arrhythmias. Hanouz et al. showed that propofol decreased the dispersion of APD between the ischemic and normal zone and decreased the occurrence of ar-
rhythmias. Although the precise mechanisms underlying the effect of propofol on ischemia-induced changes in APD and on potassium channels remain poorly studied, this effect of propofol might be involved in our results.

Intralipid, as a solvent for propofol, has been reported to have no effect on ischemia–reperfusion injury. However, the effect of Intralipid on ischemia-induced arrhythmias remains unknown. Our preliminary results demonstrated that Intralipid itself did not affect hemo-
dynamics and ischemia-induced arrhythmias. Based on these results, we believe that the use of Intralipid as a vehicle did influence the effects of propofol during ischemic conditions.

While propofol had beneficial effects on ischemia-in-
duced arrhythmias, sevoflurane lacked this effect. This absence of protection occurred in spite of sevoflurane’s well-known cardioprotective effects against myocardial dysfunction and dysrhythmias in ischemic/reperfusion models. Sevoflurane is also well known to inhibit L-type Ca$$^{2+}$$ current and this might inhibit Ca$$^{2+}$$ overload and prevent early afterdepolarizations that may con-
tribute to arrhythmias in ischemic myocardium. In con-
trast, Chae et al. showed that sevoflurane prolongs APD, which may lead to fatal ventricular arrhythmias, via suppression of transient outward currents (I$$\text{to}$$) in rat ventricular myocytes. Although it is difficult to deter-
mine the effect of sevoflurane on ischemia-induced ar-
rhythmias via various ion currents, it is certain that these actions will occur in combination with altered cell-to-cell conduction induced by ischemia. Furthermore, many studies demonstrated that sevoflurane decreases parasympathetic activity, resulting in sympathetic dom-
inance that might contribute to ischemia-induced ar-
rhythmias. In our results, it is difficult to determine if sevoflurane decreases parasympathetic more than sympa-
thetic activity, because sevoflurane caused a reduction in heart rate. However, previous studies have shown that heart rate and sympathovagal balance were not correlated during anesthesia; thus, to accurately estimate autonomic activity during anesthesia when heart rate is not at a steady state, nonlinear measures such as heart rate entropy may be preferable. Since sevoflurane has both proarrhythmic and antiarrhythmic effects, it is dif-
ficult to determine the mechanisms responsible for the proarrhythmic effect of sevoflurane on ischemia-induced arrhythmias in our study, and further investigation is required.

Anesthetics and Connexin 43

Many studies have demonstrated that Cx43 is remark-
ably reduced in ischemia and heart failure. Gene-
targeting studies demonstrate that reduced expression of Cx43 increases the incidence of ventricular tachyar-
rhythmias and causes a significant reduction in con-
duction velocity in mice during acute MI. Beardslee et al. reported that reversible Cx43 dephosphorylation could also contribute to myocardial cellular uncoupling, and thus play a role in arrhythmogenesis during acute ischemia. One potential mechanism of ischemia-induced accumulation of dephosphorylated Cx43 is decreased intracellular ATP concentration and decreased thermo-
dynamic driving force for phosphorylation (the free-
ergy change of ATP hydrolysis). The decrease in the free-energy change of ATP hydrolysis during ischemia is biphasic, with a moderate immediate decrease and a marked secondary decrease that coincides with cell-to-
cell uncoupling. Although these studies demonstrated that Cx43 is an important factor for arrhythmias during MI, the effects of anesthetics on Cx43 remain unknown.

This is the first study showing that anesthetics attenu-
ated a principal cardiac gap-junction protein, Cx43, dur-
ing MI. In our study, only propofol prevented the loss of
the increased expression of NP-Cx43, regardless of the dose, during 30 min of LAD ligation. However, the precise mechanism of the effect of propofol or sevoflurane on modulation of Cx43 remains unknown. Recent studies have demonstrated that vagal nerve stimulation prevented ventricular fibrillation after myocardial infarction in rats46 and dogs.47 Ando et al.46 reported that vagal nerve stimulation exerted an antiarrhythmic effect during acute MI by preserving phosphorylated Cx43. Several mechanisms might be involved in the linkage between vagal nerve stimulation and the preservation of protein levels of phosphorylated Cx43 during MI. Vagal nerve stimulation may activate several protein kinases and induce phosphorylation of Cx43 through muscarinic receptors.48 Our previous study42 and other studies39–41 have reported differential effects of propofol and sevoflurane on the autonomic nervous system. Propofol is believed to reduce parasympathetic tone to a lesser degree than sympathetic tone, leading to parasympathetic dominance. In contrast, sevoflurane decreases parasympathetic tone to a larger degree than sympathetic tone, leading to sympathetic dominance. Our present study suggests that these differential effects of propofol and sevoflurane on the autonomic nervous system resulted in attenuation of phosphorylated protein levels of Cx43 from our result that propofol’s action, including an action on Cx43, was blocked by atropine.

Limitations
We recognize several limitations of our study. First, although we show a remarkable benefit of propofol during acute MI in the rat model, it should be recognized that there are differences in the timing of ischemia-induced arrhythmias, electrophysiological properties, and functional morphology between rat and human patients or species. In particular, rat myocytes are known to have a much briefer action potential.49 Despite species differences, knowledge obtained from the study of anesthetic agents in mouse, rat, guinea pig, or rabbit models, and their underlying electrophysiological and metabolic mechanisms of action, has been instrumental in the development of strategies for anesthesia management in humans. Second, HR and MBP in the Prop-HD and Sevo groups tended to be lower than in the other groups. However, changes in HR and MBP did not appear to significantly influence arrhythmias or the concentration of phosphorylated-Cx43 between the Prop-LD and Prop-HD groups. Therefore, this may indicate that the range of hemodynamic changes barely affected our results. Finally, it is unclear whether the effects of propofol and sevoflurane on the phosphorylated-Cx43 are direct or indirect via the autonomic nervous system. Previous studies have demonstrated that halothane might block the gap-junction channels and cause asynchronous beating in cultured neonatal rat ventricular myocytes.50,51 Based on these findings, further investigation of the direct effects of propofol and sevoflurane on Cx43 is required.

Summary
Propofol and sevoflurane have differential effects on ischemia-induced arrhythmias via modulation of the autonomic nervous system and/or a principal gap-junction protein, Cx43. One of the mechanisms of propofol’s antiarrhythmic effect during myocardial ischemia might be preservation of phosphorylated-Cx43 protein during myocardial ischemia.

References
7. Peters NS, Green CR, Poole-Wilson PA, Severs NJ: Reduced content of connexin 43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 1993; 88:866–75
15. Leenen FH, Yuan B: Mortality after coronary artery occlusion in different models of cardiac hypertrophy in rats. Hypertension 2001; 37:209–15
20. Alphin RS, Martens JR, Dennis DM: Frequency-dependent effects of propo-
fol on atrioventricular nodal conduction in guinea pig isolated heart. Mechanism and potential antidysrhythmic properties. Anesthesiology 1995; 83:382–94


Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/110/1/50/246295/0000542-200901000-00014.pdf by guest on 07 November 2021